These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 17970510)

  • 1. Is it time to reconsider subcutaneous administration of epoetin?
    Patel TV; Robinson K; Singh AK
    Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing anaemia management with subcutaneous administration of epoetin.
    Besarab A
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi10-5. PubMed ID: 15958820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.
    Thamer M; Zhang Y; Kaufman J; Stefanik K; Cotter DJ
    Am J Kidney Dis; 2006 Jul; 48(1):77-87. PubMed ID: 16797389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: results from a Swedish multicentre survey.
    Linde T; Furuland H; Wikström B
    Scand J Urol Nephrol; 2005; 39(4):329-33. PubMed ID: 16118109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
    Holloway M
    Nephrol Nurs J; 2007; 34(5):527-31. PubMed ID: 18041455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
    Vercaigne LM; Collins DM; Penner SB
    J Clin Pharmacol; 2005 Aug; 45(8):895-900. PubMed ID: 16027399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
    Pussell BA; Walker R
    Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erythropoiesis-stimulating agents in chronic kidney disease: which route of administration?].
    Borrelli S; Baldanza D; Scigliano R; Catapano F; Grimaldi M; Calabria M; Zamboli P; Minutolo R; De Nicola L; Conte G
    G Ital Nefrol; 2009; 26(1):31-7. PubMed ID: 19255962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States.
    Wright DG; Wright EC; Narva AS; Noguchi CT; Eggers PW
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1822-30. PubMed ID: 26358266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
    Więcek A; Ahmed I; Scigalla P; Koytchev R
    Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC; Temple RM; Kwan JT
    Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous compared with intravenous epoetin treatment in patients on hemodialysis: one center study.
    Malovrh M; Premru V
    Ther Apher Dial; 2005 Jun; 9(3):233-6. PubMed ID: 15966996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once weekly treatment with epoetin-beta.
    Locatelli F
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi26-30. PubMed ID: 15958823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose tailoring strategies in haemodialysis patients: a discussion of case histories.
    Kleophas W
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi31-6. PubMed ID: 15958825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
    Berns JS
    Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisions in the prescribing information for Epoetin alfa: implications for nephrology nurses and patients on dialysis.
    Hayslip D
    Nephrol Nurs J; 2008; 35(2):163-7. PubMed ID: 18472685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Route of epoetin administration influences hemoglobin variability in hemodialysis patients.
    Patel T; Hirter A; Kaufman J; Keithi-Reddy SR; Reda D; Singh A
    Am J Nephrol; 2009; 29(6):532-7. PubMed ID: 19088467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.